Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ENLV NASDAQ:REPL NASDAQ:SLGL NASDAQ:TELO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENLVEnlivex Therapeutics$0.84+2.7%$1.00$0.66▼$2.10$199.87M1.49529,053 shs79,664 shsREPLReplimune Group$3.22+12.2%$5.89$1.50▼$13.24$265.05M0.123.85 million shs1.63 million shsSLGLSol-Gel Technologies$75.08+1.8%$79.07$6.57▼$97.97$210.99M1.1635,408 shs2,182 shsTELOTelomir Pharmaceuticals$1.34+0.8%$1.32$1.05▼$3.10$46.07M-0.21144,739 shs55,289 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENLVEnlivex Therapeutics+0.47%-0.75%-13.89%-25.47%-21.17%REPLReplimune Group+14.80%+11.67%-65.87%-59.00%-71.33%SLGLSol-Gel Technologies-2.43%+4.02%-7.16%+11.86%+1,569.00%TELOTelomir Pharmaceuticals-5.00%-8.28%+4.72%+14.66%-48.25%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENLVEnlivex Therapeutics$0.84+2.7%$1.00$0.66▼$2.10$199.87M1.49529,053 shs79,664 shsREPLReplimune Group$3.22+12.2%$5.89$1.50▼$13.24$265.05M0.123.85 million shs1.63 million shsSLGLSol-Gel Technologies$75.08+1.8%$79.07$6.57▼$97.97$210.99M1.1635,408 shs2,182 shsTELOTelomir Pharmaceuticals$1.34+0.8%$1.32$1.05▼$3.10$46.07M-0.21144,739 shs55,289 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENLVEnlivex Therapeutics+0.47%-0.75%-13.89%-25.47%-21.17%REPLReplimune Group+14.80%+11.67%-65.87%-59.00%-71.33%SLGLSol-Gel Technologies-2.43%+4.02%-7.16%+11.86%+1,569.00%TELOTelomir Pharmaceuticals-5.00%-8.28%+4.72%+14.66%-48.25%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceENLVEnlivex Therapeutics 2.00Hold$16.501,859.62% UpsideREPLReplimune Group 1.60Reduce$4.7547.52% UpsideSLGLSol-Gel Technologies 2.33Hold$110.0046.50% UpsideTELOTelomir Pharmaceuticals 2.00HoldN/AN/ACurrent Analyst Ratings BreakdownLatest TELO, REPL, SLGL, and ENLV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/24/2026REPLReplimune Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/24/2026SLGLSol-Gel Technologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C) ➝ Hold (C-)4/21/2026TELOTelomir Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/13/2026REPLReplimune Group Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Hold4/13/2026REPLReplimune Group BMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeMarket Perform ➝ Underperform4/13/2026REPLReplimune Group Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$11.00 ➝ $2.004/13/2026REPLReplimune Group Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Hold$13.00 ➝ $2.004/13/2026REPLReplimune Group WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform ➝ Neutral$19.00 ➝ $2.004/13/2026REPLReplimune Group JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral ➝ Underweight4/13/2026REPLReplimune Group HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Sell4/10/2026REPLReplimune Group Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Neutral$4.00(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookENLVEnlivex TherapeuticsN/AN/AN/AN/A$8.15 per shareN/AREPLReplimune GroupN/AN/AN/AN/A$5.40 per shareN/ASLGLSol-Gel Technologies$19.39M10.88N/AN/A$8.19 per share9.17TELOTelomir PharmaceuticalsN/AN/AN/AN/A$0.17 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateENLVEnlivex Therapeutics$1.24B-$0.55N/AN/AN/AN/A248.08%206.39%N/AREPLReplimune Group-$247.30M-$3.44N/AN/AN/AN/A-102.69%-72.22%5/28/2026 (Estimated)SLGLSol-Gel Technologies-$6.13M-$2.23N/AN/AN/A-31.60%-24.29%-18.73%5/22/2026 (Estimated)TELOTelomir Pharmaceuticals-$10.41M-$0.33N/AN/AN/AN/A-315.26%-259.29%5/13/2026 (Estimated)Latest TELO, REPL, SLGL, and ENLV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/28/2026Q4 2026REPLReplimune Group-$0.73N/AN/AN/A$0.95 millionN/A5/22/2026Q1 2026SLGLSol-Gel Technologies-$1.84N/AN/AN/A$0.90 millionN/A5/13/2026N/ATELOTelomir Pharmaceuticals-$0.07N/AN/AN/AN/AN/A3/19/2026Q4 2025SLGLSol-Gel Technologies$0.39-$1.07-$1.46-$1.06$6.50 million$0.70 million3/17/2026Q4 2025TELOTelomir Pharmaceuticals-$0.07-$0.06+$0.01-$0.06N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthENLVEnlivex TherapeuticsN/AN/AN/AN/AN/AREPLReplimune GroupN/AN/AN/AN/AN/ASLGLSol-Gel TechnologiesN/AN/AN/AN/AN/ATELOTelomir PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioENLVEnlivex TherapeuticsN/A193.24193.24REPLReplimune Group0.335.605.60SLGLSol-Gel TechnologiesN/A4.374.37TELOTelomir PharmaceuticalsN/A5.145.14Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipENLVEnlivex Therapeutics1.02%REPLReplimune Group92.53%SLGLSol-Gel Technologies26.18%TELOTelomir PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipENLVEnlivex Therapeutics12.28%REPLReplimune Group5.20%SLGLSol-Gel Technologies66.51%TELOTelomir PharmaceuticalsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableENLVEnlivex Therapeutics70237.38 million208.23 millionOptionableREPLReplimune Group21082.57 million78.28 millionOptionableSLGLSol-Gel Technologies502.81 million941,000No DataTELOTelomir Pharmaceuticals134.38 millionN/AN/ATELO, REPL, SLGL, and ENLV HeadlinesRecent News About These CompaniesTelomir Pharmaceuticals Receives FDA IND Clearance for Telomir-ZnApril 30, 2026 | tipranks.comTelomir Pharmaceuticals Announces FDA Clearance of IND for Telomir-Zn in Triple-Negative Breast CancerApril 30, 2026 | accessnewswire.comATelomir Pharmaceuticals (NASDAQ:TELO) Trading 1.4% Higher - Here's What HappenedApril 25, 2026 | americanbankingnews.comTelomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals, Securing Global Rights to Telomir-1 (Telomir-Zn)April 24, 2026 | usatoday.comTelomir Pharmaceuticals Inc.April 2, 2026 | barrons.comTelomir seeks FDA approval for Telomir-1 to treat breast cancerApril 2, 2026 | msn.comTelomir Pharmaceuticals Regains Nasdaq Listing Rule ComplianceMarch 31, 2026 | tipranks.comTelomir Pharmaceuticals Submits IND to FDA for Telomir-1 (Telomir-Zn) in Advanced and Metastatic Triple-Negative Breast CancerMarch 31, 2026 | accessnewswire.comATelomir Shareholders Approve Equity Plan and Bylaw ChangesMarch 27, 2026 | tipranks.comTelomir Pharmaceuticals Faces Crucial Corporate and Regulatory DeadlinesFebruary 21, 2026 | aktiencheck.deATelomir Sets Vote on Transformative TELI Merger and Governance ChangesFebruary 19, 2026 | tipranks.comTelomir reveals promising preclinical data for Telomir-ZnFebruary 17, 2026 | tipranks.comTelomir Pharmaceuticals Demonstrates Broad Tumor Cell Mortality in Human Triple-Negative Breast Cancer ModelsFebruary 17, 2026 | accessnewswire.comATelomir Pharmaceuticals Highlights Preclinical Data for Telomir-1February 5, 2026 | tipranks.comTelomir Pharmaceuticals Reports New Data Supporting an Epigenetic Modulation Mechanism Implicated in Cancer and AgingFebruary 5, 2026 | accessnewswire.comAFinancial Survey: Telomir Pharmaceuticals (NASDAQ:TELO) versus electroCore (NASDAQ:ECOR)January 18, 2026 | defenseworld.netDTelomir Highlights Positive Preclinical Results for Telomir-1 in TNBCJanuary 5, 2026 | tipranks.comTelomir Pharmaceuticals Announces Telomir-1 Significantly Reduced Tumor Growth and Metastases in Aggressive Triple-Negative Breast Cancer Animal ModelsJanuary 5, 2026 | accessnewswire.comATelomir Pharmaceuticals reports results from safety studies for Telomir-1December 18, 2025 | msn.comTelomir Pharmaceuticals Reports Favorable IND-Enabling GLP Safety Results for Telomir-1 Supporting First-in-Human Clinical DevelopmentDecember 18, 2025 | accessnewswire.comANew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWith Nike Shares Near a 12-Year Low, Is Now the Time to Be Brave?By Sam Quirke | April 12, 2026Bitcoin and Big Tech Rally as Risk Appetite Returns, Even With Ceasefire UncertaintyBy Jessica Mitacek | April 21, 2026The Drone Disruptor: Kratos Stock Seeks a Higher Altitude By Jeffrey Neal Johnson | April 8, 2026The PDT Rule Is On Its Way Out: 5 Stocks That Stand to Benefit the MostBy Ryan Hasson | April 20, 20263 Reasons Analysts Love DexComBy Nathan Reiff | May 5, 2026TELO, REPL, SLGL, and ENLV Company DescriptionsEnlivex Therapeutics NASDAQ:ENLV$0.84 +0.02 (+2.71%) As of 11:19 AM Eastern This is a fair market value price provided by Massive. Learn more.Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.Replimune Group NASDAQ:REPL$3.22 +0.35 (+12.20%) As of 11:21 AM Eastern This is a fair market value price provided by Massive. Learn more.Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.Sol-Gel Technologies NASDAQ:SLGL$75.08 +1.31 (+1.78%) As of 11:21 AM Eastern This is a fair market value price provided by Massive. Learn more.Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.Telomir Pharmaceuticals NASDAQ:TELO$1.34 +0.01 (+0.75%) As of 11:22 AM Eastern This is a fair market value price provided by Massive. Learn more.Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Just How Big a Problem Could Amazon’s Cash Burn Rate Be? BlackBerry Rewrites Its Own Operating System Grab Holdings Faces Hurdles, But Upside Potential Is Hard to Ignore Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
